Newsroom | 13910 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne. “Since this program began nine years ago, significant progress has b...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), líder en medicina genética de precisión para enfermedades poco frecuentes, anunció hoy la apertura oficial de Route 79, el programa de becas de Duchenne para el año académico 2026-2027. Se concederán becas académicas de hasta $5,000 a un máximo de 20 personas que tengan distrofia muscular de Duchenne y a un máximo de cinco hermanos de personas que tengan Duchenne. “Desde que este programa comenzó hace nueve años, se ha...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, an investigational gene therapy in late-stage clinical development as a potential best-in-class treatment for Rett syndrome. The Breakthrough Therapy designation was based on the F...

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--AS Software, the leader in specialty-focused ultrasound reporting solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Asera™, the next-generation version of its established ultrasound reporting platform. Asera represents an evolution of AS Software, maintaining the same intended use and core clinical functionality while introducing a redesigned user experience, enhanced workflows, and a scalable, c...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases...

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens announced today the launch of Walgreens Weight Management, a new digital healthcare offering designed to help eligible adults access personalized, clinician-guided support for weight loss. This expands Walgreens’ Virtual Healthcare platform and provides patients with convenient access to licensed doctors and nurse practitioners, FDA-approved medication options and ongoing support from the comfort of their home. The program is intended for eligible ove...

NEW YORK--(BUSINESS WIRE)--Qure.ai nets six new indications cleared by the FDA, taking the chest X-ray crown in the radiology AI race...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026. “Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acut...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “Our fourth quarter 2025 performance shows that our strategy is...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to b...